Clear All
765 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
BA Belzutifan Welireg 40mg Chemotherapy Miscellaneous Agent HIF-2 alpha Yes 2021 In Use
Mobocertinib Exkivity 40mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2021 In Use
J1952 Leuprolide Mesylate Camcevi 1mg Hormonal Therapy GnRH Agonist No 2021 Jan 26, 2022 In Use
Asciminib Scemblix 20mg,40mg Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Yes 2021 In Use
J9353 Margetuximab-cmkb Margenza 5mg Immunotherapy Monoclonal Antibody HER2 No 2021 Jul 23, 2021 In Use
Q5112 Trastuzumab-dttb Ontruzant 10mg Immunotherapy Monoclonal Antibody HER2 No 2021 Jul 1, 2019 In Use
J9071 Cyclophosphamide (AuroMedics) Cyclophosphamide 5mg Chemotherapy Alkylating Agent Nitrogen mustard No 2021 Mar 25, 2022 In Use
J1448 Trilaciclib Cosela 1mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 No 2021 Sep 27, 2021 In Use
NA Umbralisib Ukoniq 260.2mg Chemotherapy Enzyme Inhibitor PI3Kδ, CK1ε, ABL1, CXCL12, CCL19 Yes 2021 In Use
J9021 Asparaginase Erwinia Chrysanthemi (recombinant)-rywn Rylaze 0.1mg Chemotherapy Miscellaneous Agent Enzyme No 2021 Jan 26, 2022 In Use
J1954 Leuprolide acetate for depot suspension (lutrate depot) Lutrate Depot 7.5mg Hormonal Therapy GnRH Agonist No 2022 Apr 1, 2023 In Use
C9142 Bevacizumab-maly Alymsys 10mg Immunotherapy Monoclonal Antibody VEGF No 2022 Sep 27, 2022 Dec 21, 2022 No Longer Used
J9051 Bortezomib (Maia) Bortezomib 0.1mg Chemotherapy Proteasome Inhibitor 26S Yes 2022 Aug 28, 2023 In Use
J9059 Bendamustine (Baxter) Bendamustine (Baxter) 1mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2022 Jul 11, 2023 Dec 17, 2024 No Longer Used
Olutasidenib Rezlidhia 150mg Chemotherapy Enzyme Inhibitor IDH1 Yes 2022 In Use
Olutasidenib Rezlidhia 150mg Chemotherapy Enzyme Inhibitor IDH1 Yes 2022 In Use
Adagrasib Krazati 200mg Immunotherapy RAS Inhibitor KrAS G12C Yes 2022 In Use
Q5125 Filgrastim Releuko 1mcg Ancillary Therapy Immunostimulant Granulocyte colony stimulating factor No 2022 Sep 27, 2022 In Use
Q5127 Pegflilgrastim-fpgk Stimufend 0.5mg Ancillary Therapy Immunostimulant Granulocyte colony stimulating factor No 2022 Mar 17, 2023 In Use
Q5126 Bevacizumab-maly Alymsys 10mg Immunotherapy Monoclonal Antibody VEGF No 2022 Nov 28, 2022 In Use
J9296 Pemetrexed (Accord) Pemetrexed (Accord) 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2022 Mar 17, 2023 In Use
J9049 Bortezomib (Hospira) Bortezomib (Hospira) 0.1mg Chemotherapy Proteasome Inhibitor 26S No 2022 Dec 21, 2022 In Use
J9322 Pemetrexed (Bluepoint) Pemetrexed (Bluepoint) 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2022 Jul 11, 2023 In Use
J9274 Tebentafusp-tebn Kimmtrak 1mcg Immunotherapy T Cell Receptor (TCR) HLA-A*02:01 No 2022 Sep 27, 2022 In Use
J9314 Pemetrexed (Teva) Pemetrexed (Teva) 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2022 Dec 21, 2022 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.